Dermatology Times, May 2020 (Vol. 41, No. 5)

A variety of topical and injectable therapies are showing promise for addressing the problem of hair loss in both men and women, says Matt Leavitt, D.O.

Use of systemic therapies for treatment of melanoma is growing, and so is the list of cutaneous side effects associated with their use.

The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.

Mast cells appear to play an intricate role in the pathophysiology of rosacea and could serve as potential targets for future therapies, according to recent study findings.

It is estimated that 0.025% to 16% of all actinic keratosis (AK) lesions may progress into invasive SCC per year, and there is still no marker to predict which lesions will progress, according to a recent paper that outlined diagnostic challenges as well as current and pipeline treatment approaches.

Recent evidence of increased mast cell activity suggests mast cell stabilization as a target for rosacea treatment.

Zoe Diana Draelos, M.D, discusses prebiotic, probiotic and postbiotic skincare products and their role in normalizing the skin microbiome.

Read one New York physician's insights on practice survival and patient care during the pandemic.

David J. Goldberg, M.D., J.D., discusses important considerations regarding telemedicine and HIPAA compliance that dermatologists should keep in mind during the COVID-19 pandemic.

Speaking about device-based acne treatments at Maui Derm for Dermatologists 2020 meeting, Fernanda Sakamoto, Ph.D., M.D., discussed PDT and other approaches for targeting the sebaceous gland.

Hilary E. Baldwin, M.D. discusses advances in acne treatment that have expanded treatment options, allowing physicians to improve outcomes in patients with moderate-to-severe acne.

A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.

Dermatologists often combine multiple topical agents on their own, and have been doing so for many years. However, extemporaneous compounding of psoriasis topical agents may not necessarily yield what dermatologists anticipate.

Soliton has received 510(k) clearance from the U.S. FDA for its Generation II Rapid Acoustic Pulse (RAP) device for tattoo removal.

Melasma responds well to oral and locally injected tranexamic acid treatments, but clinical results from topical tranexamic acid administration have been disappointing, researchers report. They examined efficacy of a co-enhancer as a method to deliver the treatment.

A recent study reports findings that support dupilumab as a safe, long-term treatment in patients with moderate-to-severe atopic dermatitis.

With advancements in deep next-generation sequencing (NGS) and bioinformatics analysis, the authors of a recent study suggest the skin microbiome may hold promise as a clinical biomarker in atopic dermatitis (AD) management.